ReviewCurrent neuropharmacology2018
Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects.
Review in Current neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 6 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- The effect of olanzapine on lipid profiles in humans: a time and dose response meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2026Pooled it
- Switching antipsychotics versus continued current treatment in people with non-responsive schizophrenia.The Cochrane database of systematic reviews · 2025Pooled it
- Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials.Schizophrenia bulletin · 2024Pooled it
- Meta-analysis of peripheral insulin-like growth factor 1 levels in schizophrenia.Brain and behavior · 2023Pooled it
- Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.Schizophrenia bulletin · 2022Pooled it
- The Association Between Personality Traits and Dietary Choices: A Systematic Review.Advances in nutrition (Bethesda, Md.) · 2021Pooled it
- Do proinflammatory cytokines play a role in clozapine-associated glycometabolism disorders?Psychopharmacology · 2021Trial
- Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.Psychopharmacology · 2020Trial
- Sex-specific effects of the atypical antipsychotic risperidone on performance in a risky decision-making task.Behavioural brain research · 2027Article
- Brain functional connectivity patterns associated with adiposity in schizophrenia.Psychiatry research. Neuroimaging · 2026Article
- Clinical Intervention Following Detection of Incident Diabetes Within a Large Psychiatric Service System: A Chart Review Study.Acta psychiatrica Scandinavica · 2026Article
- Anti-psychotic therapeutics modify gut microbial metabolism and modulate susceptibility to gastrointestinal infection in mice.bioRxiv : the preprint server for biology · 2026Article
- Functional coupling between MC4R and Kir7.1 contributes to clozapine-induced weight gain in female mice.Nature communications · 2026Article
- Long-term effects of adolescent risperidone treatment on the mouse cortex.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence.CNS drugs · 2026Review
- Article
- Molecular Dynamics and Electron Density Topology Reveal Ligand-Specific Interaction Patterns at the Dopamine DInternational journal of molecular sciences · 2026Article
- Genetic overlap between treatment-resistant schizophrenia and smoking initiation.The international journal of neuropsychopharmacology · 2026Article
- Neural circuits regulating activity-based anorexia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntipsychotic-induced metabolic side effects are major concerns in psychopharmacology and clinical psychiatry. Their pathogenetic mechanisms are still not elucidated.
methodsHerein, we review the impact of neurotransmitters on metabolic regulation, providing insights into antipsychotic-induced metabolic side effects.
resultsAntipsychotic drugs seem to interfere with feeding behaviors and energy balance, processes that control metabolic regulation. Reward and energy balance centers in central nervous system constitute the central level of metabolic regulation. The peripheral level consists of skeletal muscles, the liver, the pancreas, the adipose tissue and neuroendocrine connections. Neurotransmitter receptors have crucial roles in metabolic regulation and they are also targets of antipsychotic drugs. Interaction of antipsychotics with neurotransmitters could have both protective and harmful effects on metabolism.
conclusionEmerging evidence suggests that antipsychotics have different liabilities to induce obesity, diabetes and dyslipidemia. However this diversity cannot be explained merely by drugs'pharmacodynamic profiles, highlighting the need for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.